The global PARP Inhibitor Market is estimated to be valued at USD 6.60 Bn in 2022 and is expected to exhibit a CAGR of 13.09% over the forecast period 2023-2031, as highlighted in a new report published by Coherent Market Insights.
A) Market Overview:
PARP inhibitors are a class of drugs that inhibit the enzyme poly (ADP-ribose) polymerase (PARP). These inhibitors have gained significant attention in the field of oncology due to their ability to target cancer cells ... Read more
PARP (Poly ADP-Ribose Polymerase) inhibitors are drugs that act on the DNA damage response pathway by targeting PARP enzymes. PARP inhibitors have emerged as an important class of anti-cancer drugs as they can treat certain cancers with defective homologous recombination repair like BRCA gene mutations.
The Global PARP Inhibitor Market Sizeis estimated to be valued ... Read more
